X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (8720) 8720
Newsletter (1030) 1030
Book Review (1013) 1013
Publication (393) 393
Magazine Article (48) 48
Conference Proceeding (42) 42
Newspaper Article (32) 32
Book Chapter (17) 17
Dissertation (15) 15
Trade Publication Article (9) 9
Paper (3) 3
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
pravastatin (7401) 7401
index medicus (6552) 6552
humans (5716) 5716
male (3998) 3998
female (3320) 3320
middle aged (2782) 2782
statins (2214) 2214
aged (2166) 2166
cholesterol (2150) 2150
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (1994) 1994
simvastatin (1982) 1982
pravastatin - therapeutic use (1776) 1776
cardiac & cardiovascular systems (1774) 1774
pharmacology & pharmacy (1628) 1628
adult (1579) 1579
prevention (1447) 1447
atorvastatin (1379) 1379
animals (1370) 1370
abridged index medicus (1360) 1360
anticholesteremic agents - therapeutic use (1318) 1318
risk factors (1283) 1283
hypercholesterolemia (1279) 1279
atherosclerosis (1136) 1136
cholesterol, ldl - blood (1126) 1126
hypercholesterolemia - drug therapy (1090) 1090
treatment outcome (1062) 1062
risk (1052) 1052
pravastatin - pharmacology (1033) 1033
coronary-heart-disease (990) 990
medicine, general & internal (984) 984
peripheral vascular disease (945) 945
hydroxymethylglutaryl-coa reductase inhibitors - pharmacology (935) 935
events (912) 912
cholesterol - blood (907) 907
research (906) 906
myocardial-infarction (901) 901
antilipemic agents (896) 896
atorvastatin calcium (856) 856
men (827) 827
lovastatin (776) 776
drug therapy (763) 763
therapy (694) 694
coronary heart disease (679) 679
mortality (678) 678
disease (668) 668
lipids (663) 663
drugs (656) 656
cardiovascular disease (640) 640
rats (640) 640
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (631) 631
heptanoic acids - therapeutic use (594) 594
double-blind method (583) 583
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (574) 574
cardiovascular agents (572) 572
pravastatin - administration & dosage (568) 568
analysis (563) 563
simvastatin - therapeutic use (545) 545
pyrroles - therapeutic use (542) 542
triglycerides - blood (524) 524
statin (518) 518
care and treatment (509) 509
time factors (506) 506
prospective studies (505) 505
lipids - blood (497) 497
c-reactive protein (496) 496
coronary disease - prevention & control (496) 496
hypercholesterolemia - blood (494) 494
inflammation (493) 493
follow-up studies (490) 490
cholesterol, hdl - blood (483) 483
dose-response relationship, drug (482) 482
coa reductase inhibitors (474) 474
heart-disease (470) 470
medical research (465) 465
aged, 80 and over (461) 461
randomized controlled trials as topic (447) 447
hyperlipidemias - drug therapy (441) 441
rosuvastatin (440) 440
cardiovascular diseases - prevention & control (436) 436
low density lipoproteins (436) 436
efficacy (429) 429
reports (427) 427
universities and colleges (427) 427
anticholesteremic agents - pharmacology (426) 426
cardiovascular-disease (425) 425
hypolipidemic agents - therapeutic use (416) 416
coronary heart-disease (403) 403
mice (399) 399
primary prevention (399) 399
health aspects (387) 387
drug therapy, combination (382) 382
pravastatin - adverse effects (382) 382
safety (382) 382
fluvastatin (379) 379
cardiovascular diseases (376) 376
diabetes (375) 375
hmg-coa reductase (373) 373
hypertension (366) 366
anticholesteremic agents - administration & dosage (360) 360
medicine, experimental (357) 357
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (9183) 9183
German (140) 140
Spanish (125) 125
French (102) 102
Japanese (95) 95
Russian (67) 67
Chinese (44) 44
Italian (38) 38
Portuguese (29) 29
Czech (8) 8
Korean (6) 6
Norwegian (6) 6
Swedish (6) 6
Polish (5) 5
Danish (4) 4
Dutch (4) 4
Serbian (3) 3
Hungarian (2) 2
Finnish (1) 1
Slovak (1) 1
Slovenian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cell Biology International, ISSN 1065-6995, 05/2007, Volume 31, Issue 5, p. 451
Recent studies suggest that treatment with PPAR-[gamma] agonists and statins have beneficial effects on renal disease. However, the combined effects of... 
Pravastatin
Journal Article
American Journal of Obstetrics and Gynecology, ISSN 0002-9378, 2016, Volume 214, Issue 6, pp. 720.e1 - 720.e17
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2005, Volume 352, Issue 1, pp. 20 - 28
Statin therapy lowers not only low-density lipoprotein (LDL) cholesterol levels, but also levels of C-reactive protein (CRP), a marker of inflammation. This... 
MEDICINE, GENERAL & INTERNAL | DENSITY-LIPOPROTEIN CHOLESTEROL | HEART-DISEASE | TREATMENT PANEL-III | INFLAMMATION | CARDIOVASCULAR-DISEASE | RISK | ACUTE CORONARY SYNDROMES | UNSTABLE ANGINA | PRAVASTATIN | PRIMARY PREVENTION | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Myocardial Infarction - blood | Heptanoic Acids - therapeutic use | Humans | Middle Aged | Male | Secondary Prevention | Coronary Disease - mortality | Incidence | C-Reactive Protein - metabolism | Pyrroles - administration & dosage | Heptanoic Acids - administration & dosage | Cholesterol, LDL - blood | Female | C-Reactive Protein - drug effects | Pyrroles - therapeutic use | Pravastatin - therapeutic use | Heptanoic Acids - pharmacology | Pravastatin - pharmacology | Coronary Disease - blood | Risk Factors | Proportional Hazards Models | Cholesterol, LDL - drug effects | Fluoroquinolones - therapeutic use | Biomarkers - blood | Atorvastatin Calcium | Coronary Disease - prevention & control | Pyrroles - pharmacology | Anticholesteremic Agents - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Myocardial Infarction - drug therapy | Pravastatin - administration & dosage | Anticholesteremic Agents - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Myocardial Infarction - prevention & control | Anticholesteremic Agents - pharmacology | Cardiovascular disease | Heart attacks | Cholesterol | Statins | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Pharmaceutical Research, ISSN 0724-8741, 10/2012, Volume 29, Issue 10, pp. 2860 - 2873
To develop physiologically based pharmacokinetic (PBPK) model to predict the pharmacokinetics and drug-drug interactions (DDI) of pravastatin, using the in... 
Biomedical Engineering | Biochemistry, general | Biomedicine | transporters | Pharmacy | physiologically based pharmacokinetic (PBPK) model | pravastatin | Medical Law | Pharmacology/Toxicology | drug-drug interaction | OATP1B1 | Drug-Drug interaction | Transporters | Physiologically based pharmacokinetic (PBPK) model | Pravastatin | COA REDUCTASE INHIBITORS | INTERINDIVIDUAL DIFFERENCES | HEALTHY-SUBJECTS | TRANSPLANT PATIENTS | HEPATIC-UPTAKE | CHEMISTRY, MULTIDISCIPLINARY | PHYSICOCHEMICAL PROPERTIES | CYCLOSPORINE-A | PHARMACOKINETICS | TISSUE DISTRIBUTION | IN-VIVO | PHARMACOLOGY & PHARMACY | Rifampin - pharmacokinetics | Area Under Curve | Humans | Middle Aged | Male | Hepatocytes - metabolism | Enzyme Inhibitors - administration & dosage | Young Adult | Drug Interactions | Biological Transport | Enzyme Inhibitors - pharmacokinetics | Computer Simulation | Cyclosporine - pharmacokinetics | Adult | Female | Rifampin - administration & dosage | Gemfibrozil - administration & dosage | Pravastatin - pharmacology | Organic Anion Transporters - antagonists & inhibitors | Liver - metabolism | Cells, Cultured | Gemfibrozil - pharmacokinetics | Pravastatin - administration & dosage | Adolescent | Cyclosporine - administration & dosage | Aged | Solute Carrier Organic Anion Transporter Family Member 1b1 | Pravastatin - pharmacokinetics | Pharmacology | Kinetics | Pharmaceutical sciences | Statins | Index Medicus
Journal Article
International Journal of Pharmaceutics, ISSN 0378-5173, 12/2015, Volume 496, Issue 2, pp. 518 - 525
Wiechers’ programme “Formulating for Efficacy” initiated a new strategy to optimise the oil phase of topical formulations in order to achieve optimal... 
Transdermal delivery | Delivery gap theory | Pravastatin | Formulation | Wiechers | Franz cell | PHARMACOLOGY & PHARMACY | SKIN | Pravastatin - administration & dosage | Administration, Cutaneous | Diffusion | Ointments | Chemistry, Pharmaceutical | Pravastatin - pharmacokinetics | Pravastatin - chemistry | Transdermal medication | Antilipemic agents | Index Medicus
Journal Article
BMJ : British Medical Journal, ISSN 0959-8138, 5/2013, Volume 346, Issue 7911, pp. 14 - 14
Objective To examine the risk of new onset diabetes among patients treated with different HMG-CoA reductase inhibitors (statins).Design Population based cohort... 
RESEARCH | Secondary prevention | Depopulation | Population growth | Diabetes | Older adults | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | THERAPY | EVENTS | CHOLESTEROL | CORONARY | DISEASE | PREVENTION | RANDOMIZED CONTROLLED-TRIAL | MELLITUS | ATORVASTATIN | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Simvastatin - adverse effects | Cardiovascular Diseases - prevention & control | Humans | Male | Fluorobenzenes - administration & dosage | Heptanoic Acids - adverse effects | Diabetes Mellitus, Type 2 - epidemiology | Incidence | Dose-Response Relationship, Drug | Pyrroles - administration & dosage | Cardiovascular Diseases - epidemiology | Heptanoic Acids - administration & dosage | Pravastatin - adverse effects | Pyrroles - adverse effects | Diabetes Mellitus, Type 2 - etiology | Female | Retrospective Studies | Odds Ratio | Dyslipidemias - drug therapy | Pyrimidines - administration & dosage | Simvastatin - administration & dosage | Proportional Hazards Models | Rosuvastatin Calcium | Treatment Outcome | Atorvastatin Calcium | Dyslipidemias - epidemiology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Pravastatin - administration & dosage | Ontario - epidemiology | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Aged | Fluorobenzenes - adverse effects | Diabetes Mellitus, Type 2 - chemically induced | Population Surveillance | Sulfonamides - administration & dosage | Cohort Studies | Inhibitor drugs | Risk assessment | Statins | Clinical outcomes | Index Medicus | Abridged Index Medicus
Journal Article
Circulation, ISSN 0009-7322, 03/2016, Volume 133, Issue 11, pp. 1073 - 1080
BACKGROUND—Extended follow-up of statin-based low-density lipoprotein cholesterol lowering trials improves the understanding of statin safety and efficacy.... 
Heart failure | Clinical trial [publication type] | Safety | Primary prevention | Coronary disease | MORTALITY | heart failure | ETIOLOGY | clinical trial [publication type] | COST-EFFECTIVENESS | CARDIAC & CARDIOVASCULAR SYSTEMS | EVENTS | RISK | coronary disease | safety | MEN | primary prevention | CARDIOVASCULAR-DISEASE | PERIPHERAL VASCULAR DISEASE | PRAVASTATIN | OPACITIES | SIMVASTATIN | Randomized Controlled Trials as Topic - statistics & numerical data | Follow-Up Studies | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Mortality | Proportional Hazards Models | Hospitalization - statistics & numerical data | Neoplasms - mortality | Male | Scotland - epidemiology | Hypercholesterolemia - drug therapy | Cause of Death | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Survival Analysis | Cardiovascular Diseases - mortality | Diabetes Complications - epidemiology | Pravastatin - adverse effects | Cholesterol, LDL - blood | Diabetes Mellitus - mortality | Pravastatin - therapeutic use | Treatment outcome | Care and treatment | Safety and security measures | Analysis | Cholesterol, LDL | Dosage and administration | Coronary heart disease | Health aspects | Statins | Index Medicus | Abridged Index Medicus | 10062 | 10034 | 10069 | Original
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2009, Volume 54, Issue 17, pp. 1609 - 1616
Objectives We sought to identify single nucleotide polymorphisms associated with mild statin-induced side effects. Background Statin-induced side effects can... 
Cardiovascular | Internal Medicine | clinical trial | hydroxymethylglutaryl-CoA reductase inhibitors | adverse events | single nucleotide polymorphisms | myopathy | pharmacogenetics | TRIALS | CARDIAC & CARDIOVASCULAR SYSTEMS | ACID | SAFETY | SLCO1B1 POLYMORPHISM | INDUCED MYOPATHY | ATORVASTATIN | PHARMACOKINETICS | DISEASE | PRAVASTATIN | LACTONE | Haplotypes | Pyrroles - pharmacokinetics | Simvastatin - adverse effects | Heptanoic Acids - pharmacokinetics | Humans | Middle Aged | Male | Heptanoic Acids - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Organic Anion Transporters - genetics | Pravastatin - adverse effects | Pyrroles - adverse effects | Female | Muscular Diseases - chemically induced | Hypolipidemic Agents - adverse effects | Creatine Kinase - blood | Simvastatin - pharmacokinetics | Muscular Diseases - blood | Atorvastatin Calcium | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Aged | Polymorphism, Single Nucleotide | Hypolipidemic Agents - pharmacokinetics | Solute Carrier Organic Anion Transporter Family Member 1b1 | Pravastatin - pharmacokinetics | Enzymes | Hypotheses | Acids | Mortality | Cardiovascular disease | Muscle pain | Drug therapy | Statins | Cholesterol | Index Medicus | Abridged Index Medicus | muscular diseases | hydroxymethylglutaryl-CoA Reductase Inhibitors
Journal Article